Lisa Kopas, MD
Pulmonary Disease · Houston, TXNPI 1174795157
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 87.4% of it on its own, with 15 other manufacturers making up the rest. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 200 payments — averaging $600.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$105K
- Pulmonx Corporation$9K
- Intuitive Surgical$4K
- Johnson & Johnson$440
- Boston Scientific$382
- Olympus America Inc.$196
- plus $876 from 10 others
Across 72 payments — averaging $4797.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$139K
- Galvanize Therapeutics, Inc$120K
- Pulmonx Corporation$84K
- AstraZeneca$2K
What the payments were for
- Consulting fees$44,29537%
- Speaking & faculty fees$54,90046%
- Travel & lodging$13,05511%
- Food & beverage$4,9294%
- Education$3,0002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 116 | $105,056 |
| Pulmonx Corporation | 30 | $8,787 |
| Intuitive Surgical | 6 | $4,442 |
| Johnson & Johnson | 2 | $440 |
| Boston Scientific | 2 | $382 |
| Olympus America Inc. | 3 | $196 |
| GSK | 8 | $196 |
| AstraZeneca | 2 | $144 |
| Inspire Medical Systems, Inc. | 6 | $137 |
| Electromed, Inc. | 10 | $104 |
| Sanofi | 5 | $96 |
| Insmed, Inc. | 4 | $77 |
| Olympus Corporation Of The Americas | 1 | $42 |
| Pfizer | 2 | $35 |
| United Therapeutics Corporation | 2 | $26 |
| Ambu Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$66,072
- ZEPHYR ENDOBRONCHIAL VALVE$6,321
- CHARTIS CATHETER$3,641
- ZEPHYR DELIVERY CATHETER$3,641
- PULMONX CHARTIS TABLET CONSOLE$3,641
- ION$3,000
- Pulmonx Endobronchial Valve EBV$1,967
- DA VINCI SP$1,300
- MONARCH$365
- GENERAL - THERAPIES$285
- TEZSPIRE$125
How this compares
$120,179 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 375 | $290,847 |
| OfevNintedanib Esylate | 20 | $277,105 |
| Breo ElliptaFluticasone/Vilanterol | 249 | $116,613 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $107,630 |
| Spiriva RespimatTiotropium Bromide | 94 | $77,152 |
| DuleraMometasone/Formoterol | 77 | $33,286 |
| Arnuity ElliptaFluticasone Furoate | 92 | $22,204 |
| Incruse ElliptaUmeclidinium Bromide | 58 | $20,621 |
| SymbicortBudesonide/Formoterol Fumarate | 59 | $20,301 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $20,187 |
| EliquisApixaban | 18 | $13,482 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $11,790 |
| Atrovent HfaIpratropium Bromide | 25 | $11,244 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $10,734 |
| Advair HfaFluticasone Propion/Salmeterol | 24 | $9,184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta, Anoro Ellipta | $196 | $462,074795 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $105,056 | $374,444151 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $144 | $31,03571 claims |
| PfizerEliquis | $35 | $13,48218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Nicola HananiaHouston$1.3M
- Sandeep SahayHouston$378K
- Zeenat SafdarHouston$291K
- Howard HuangHouston$194K
- Brandy McKelvyHouston$168K
- Alexander StadnykHouston$158K
- Sandeep GuptaHouston$118K
- Roberto CasalHouston$113K
- Dileep PuppalaHouston$108K
- Phuongdung NguyenHouston$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.